Keywords: Ipsen, 2009 financial results
France’s Ipsen sees 2009 sales up 7.6% and rise 8.2% in fourth quarter
Article | 02 February 2010
French drugmaker Ipsen said pharmaceutical sales in 2009 - excluding foreign exchange impacts grew by a strong 7.6% year-on-year. Consolidated group sales ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
